Adrenal Cortex Carcinoma

News alerts, weekly reports and conference planners

No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	mitotane Sensitive: A1 - Approval mitotane Sensitive : A1	mitotane Sensitive: A1 - Approval mitotane Sensitive : A1
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin + etoposide IV Sensitive: A2 - Guideline cisplatin + etoposide IV Sensitive : A2	cisplatin + etoposide IV Sensitive: A2 - Guideline cisplatin + etoposide IV Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive : A2	cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	carboplatin + etoposide IV + mitotane Sensitive: A2 - Guideline carboplatin + etoposide IV + mitotane Sensitive : A2	carboplatin + etoposide IV + mitotane Sensitive: A2 - Guideline carboplatin + etoposide IV + mitotane Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	carboplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline carboplatin + doxorubicin hydrochloride + etoposide IV Sensitive : A2	carboplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline carboplatin + doxorubicin hydrochloride + etoposide IV Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive : A2	carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin + etoposide IV + mitotane Sensitive: A2 - Guideline cisplatin + etoposide IV + mitotane Sensitive : A2	cisplatin + etoposide IV + mitotane Sensitive: A2 - Guideline cisplatin + etoposide IV + mitotane Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + etoposide IV Sensitive : A2	cisplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + etoposide IV Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	streptozocin Sensitive: A2 - Guideline streptozocin Sensitive : A2	streptozocin Sensitive: A2 - Guideline streptozocin Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	mitotane + streptozocin Sensitive: A2 - Guideline mitotane + streptozocin Sensitive : A2	mitotane + streptozocin Sensitive: A2 - Guideline mitotane + streptozocin Sensitive : A2
MSI-H/dMMR	Adrenal Cortex Carcinoma	MSI-H/dMMR	Adrenal Cortex Carcinoma	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
RRM1 underexpression	Adrenal Cortex Carcinoma	RRM1 underexpression	Adrenal Cortex Carcinoma	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3
TMB-L	Adrenal Cortex Carcinoma	TMB-L	Adrenal Cortex Carcinoma	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3
MSH2 mutation	Adrenal Cortex Carcinoma	MSH2 mutation	Adrenal Cortex Carcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
FGFR3-TACC3 fusion	Adrenal Cortex Carcinoma	FGFR3-TACC3 fusion	Adrenal Cortex Carcinoma	erdafitinib Sensitive: C4 – Case Studies erdafitinib Sensitive : C4	erdafitinib Sensitive: C4 – Case Studies erdafitinib Sensitive : C4
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	rubitecan Sensitive: D – Preclinical rubitecan Sensitive : D	rubitecan Sensitive: D – Preclinical rubitecan Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	teniposide Sensitive: D – Preclinical teniposide Sensitive : D	teniposide Sensitive: D – Preclinical teniposide Sensitive : D
CDK1 overexpression	Adrenal Cortex Carcinoma	CDK1 overexpression	Adrenal Cortex Carcinoma	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
CDK4 overexpression	Adrenal Cortex Carcinoma	CDK4 overexpression	Adrenal Cortex Carcinoma	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	etoposide oral Sensitive: D – Preclinical etoposide oral Sensitive : D	etoposide oral Sensitive: D – Preclinical etoposide oral Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	pirarubicin Sensitive: D – Preclinical pirarubicin Sensitive : D	pirarubicin Sensitive: D – Preclinical pirarubicin Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	mitoxantrone Sensitive: D – Preclinical mitoxantrone Sensitive : D	mitoxantrone Sensitive: D – Preclinical mitoxantrone Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	idarubicin hydrochloride Sensitive: D – Preclinical idarubicin hydrochloride Sensitive : D	idarubicin hydrochloride Sensitive: D – Preclinical idarubicin hydrochloride Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	doxorubicin hydrochloride Sensitive: D – Preclinical doxorubicin hydrochloride Sensitive : D	doxorubicin hydrochloride Sensitive: D – Preclinical doxorubicin hydrochloride Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	daunorubicin Sensitive: D – Preclinical daunorubicin Sensitive : D	daunorubicin Sensitive: D – Preclinical daunorubicin Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	aclarubicin Sensitive: D – Preclinical aclarubicin Sensitive : D	aclarubicin Sensitive: D – Preclinical aclarubicin Sensitive : D
AURKB overexpression	Adrenal Cortex Carcinoma	AURKB overexpression	Adrenal Cortex Carcinoma	mitotane + AMG 900 Sensitive: D – Preclinical mitotane + AMG 900 Sensitive : D	mitotane + AMG 900 Sensitive: D – Preclinical mitotane + AMG 900 Sensitive : D
AURKA overexpression	Adrenal Cortex Carcinoma	AURKA overexpression	Adrenal Cortex Carcinoma	mitotane + AMG 900 Sensitive: D – Preclinical mitotane + AMG 900 Sensitive : D	mitotane + AMG 900 Sensitive: D – Preclinical mitotane + AMG 900 Sensitive : D
AURKA overexpression	Adrenal Cortex Carcinoma	AURKA overexpression	Adrenal Cortex Carcinoma	AMG 900 Sensitive: D – Preclinical AMG 900 Sensitive : D	AMG 900 Sensitive: D – Preclinical AMG 900 Sensitive : D

Adrenal Cortex Carcinoma

Associations(37)

Associations
(37)